27th of April 2026; Cambridge, UK
Cellestial Health, a biopharmaceutical company developing a new class of drugs for Parkinson’s which affects over 10 million people in the world, is pleased to have recently joined the portfolio of the Cambridge Venture Index Fund (CVIF) of ET Capital – a fund supporting diversified deep science companies spinning out of Cambridge and Oxford research ecosystems based on the findings that the investment returns from the Cambridge Cluster have outperformed the FTSE 100 index since 2005. In addition to the seed investment, ET Capital brings targeted and strategic support to ventures.
Dr Nat Hastings, CEO of Cellestial Health noted:
“Innovative businesses need appropriate support from investors who have not only capital but also networks, experience, and shared vision to help us evolve. ET Capital’s Venture Index investing approach brings that as we continue our R&D efforts for the benefit of the patients”
Martin Rigby, Managing Director of ET Capital said:
“ET Capital is delighted to have invested in Cellestial Health – a business focused on protecting brain networks to prevent diseases such as Parkinson’s which strikes 20,000 people annually in the UK. Cellestial is the third investment made by the Cambridge Venture Index Fund SEIS/EIS Fund 1 – a novel fund looking to give investors broad exposure to the best deep science businesses coming out of the Cambridge cluster – Europe’s pre-eminent technology cluster. We’re excited by the potentially life-changing difference that Nataly Hastings and her team can make on human health”
In addition to CVIF, Cellestial secured strategic advice from carefully selected sophisticated high-net worth individuals with specific experience of the sector.
Dominic O’Regan, a new-to-Cellestial angel investor with pharmaceutical industry background and over 35 portfolio investments completed to date, commented:
“Cellestial Health has ground-breaking science with the potential to produce treatments that will address the unmet needs of significant numbers of Parkinson’s Disease patients. Nat Hastings is a world leader in her field, and she and the team demonstrated clear thinking on how to develop the company and reach critical scientific and commercial milestones”
Further, existing angel investors continue their support of the company as the team prepares for the next stages of growth scientifically and commercially.
Iain Pelling who previously invested in Cellestial Health added:
“I’m so pleased to continue supporting Cellestial Health’s mission. The team has already made great strides in understanding the complex biology they are targeting, and they have the resources to establish the right testing platforms and to ensure that they can screen potential treatments at scale in the next phase. I’m very optimistic about the real-world impact their work will have”
About Cellestial Health:
Cellestial Health is a therapeutics development company which spun out from the University of Cambridge in 2023 to create new treatments for Parkinson’s and other conditions of the brain. It targets previously overlooked brain cells called astrocytes to offer new opportunities for disease modification. The lead asset family of Cellestial composed of small molecule drugs and peptides is at a preclinical stage. Since its inception, Cellestial Health secured over £980k via dilutive and non-dilutive funding routes.
Visit cellestialhealth.com to find out more.
LinkedIn: https://www.linkedin.com/company/105828196
About ET Capital:
ET Capital, founded in 1992, is an investor in high-growth technology businesses based in southern England. The firm has raised and managed a series of funds focused mainly on the globally significant cluster of science-based companies around Cambridge, Oxford and London. Managed by executive directors Martin Rigby and James Griffiths and non-executive director David Gill, ET Capital has a 32-year track record of backing businesses in the Cambridge ecosystem. For more information, visit etcapital.com
Photo: Dr Nat Hastings is holding a model of the human brain which highlights areas commonly affected by Parkinson’s, including the basal ganglia and cerebral cortex. Brain model credit: COSA LTD